TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04198649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment and azithromycin treatment
Description: Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal treatment and placebo treatment
Description: Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions
Study: NCT06549348

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Measure average procedure fluoroscopy time using LumiGuide and conventional fluoroscopy guidance
Description: Fenestrated Endovascular Aortic Repair (FEVAR) procedure done with either LumiGuide or conventional fluoroscopy guidance
Study: NCT05781815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dynamic hip screw
Description: using dynamic hip screw in treatment of trochanteric fracture and dynamic hip screw with trochanteric stabilizing plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dynamic hip screw
Description: using dynamic hip screw in treatment of trochanteric fracture and dynamic hip screw with trochanteric stabilizing plate
Study: NCT05616767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on self-screening and HPV vaccination administration
Description: Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
Study: NCT01003028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil (Limited) - Target Controlled Infusion system
Description: Limit max plasma concentration to 9.8 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil (Control) - Target Controlled Infusion system
Description: Use 20 ng/ml as max plasma concentration
Study: NCT06245018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNK Injection
Description: Subjects will receive about 4 cycles of iNK
Study: NCT06069570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB-GDT-01
Description: KB-GDT-01 is an allogeneic, gamma delta T-cell suspension product manufactured from the isolation of healthy donor peripheral blood mononuclear cells (PBMC). The KB-GDT-01 cells are cryopreserved in vapor phase liquid nitrogen (LN2) in 50 mL CryoMACS® cryobags for a total of 200 × 106 viable cells/bag. The KB-GDT-01 cryopreserved product is thawed and administered intravenously (IV) until the entire bag is infused by gravity. Low dose radiotherapy (LDRT) will be administered to selected tumor sites (maximum of 5 isocenters) at 1.0 Gy/fraction on Days 1 and 2, followed by the KB-GDT-01 IV infusion on Day 3. LDRT will be repeated on Days 8 and 9, and the 2nd KB-GDT-01 IV infusion on Day 10.
Study: NCT06015009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom management mobile health application with personalised support
Description: Other: Symptom management mobile health application with personalised support Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience.
Study: NCT05558579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No sling use
Description: Patients will not use standard of care sling
Study: NCT05323344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-physiotherapy
Description: Neuro-Physiotherapy will be done in Intervention group I

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of metacognitive behavioral therapy and Neuro-physiotherapy
Description: Combination of metacognitive behavioral therapy and Neuro-physiotherapy will be done in intervention group II
Study: NCT04910620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCI378
Description: TCI378 (Lactobacillus plantarum TCI378)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCI507
Description: TCI507 (Lactobacillus plantarum TCI507)
Study: NCT05393492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy and Radically Open dialectical behavior therapy
Description: Dialectical Behavior Therapy is a third wave cognitive-behavioral therapy. It focuses on emotional dysregulation and interactions between the patient and his family in genesis and maintenance of challenging behaviors. It is used here in an adapted form for cognitive problems.~Delivered in a group format of 19 weeks + individual sessions.
Study: NCT05807594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMZ 2.0 Intervention
Description: The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Intervention
Description: Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
Study: NCT04803565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made shoe insole
Description: Subjects will receive a custom-made shoe insole designed on the patient's foot and shoes. The subjects should wear the insole for at least 6 hours per day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham conventional Insole
Description: Subjects will receive a conventional insole without any specific property (sham insole)
Study: NCT06428643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlamydia, gonorrhea, syphilis, and HIV screening
Description: Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.
Study: NCT06134882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Monetary incentives are delivered via reloadable debit card based on verified engagement in target behaviors, including drug abstinence, appointment attendance, and completion of self-paced cognitive behavior therapy modules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy Modules
Description: Self-paced cognitive-behavior therapy modules delivered via smartphone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Contingency Management (CM) Guide
Description: Peer supports delivered via telehealth. Support is informed by the community reinforcement approach and includes motivational interviewing

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Drug testing
Description: Self-performed salivary drug testing with incentives contingent upon proper completion of test procedures as confirmed by video.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wellness modules
Description: Basic health and wellness information delivered via self-paced learning modules.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Peer technical support
Description: Peer support for promoting engagement and addressing technical issues delivered via a mobile digital platform.
Study: NCT05755581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal Antineoplastics
Description: the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.
Study: NCT04618094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bicycle ergometer training with different intensities
Description: Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
Study: NCT06110078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Oral rinse with acetazolamide (not taken orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Oral rinse with acetazolamide (not taken orally)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetazolamide
Description: Oral rinse with acetazolamide (not taken orally)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetazolamide
Description: Oral rinse with acetazolamide (not taken orally)
Study: NCT04618094

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bicycle ergometer training with different intensities
Description: Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
Study: NCT05158595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming low intensity group
Description: wobble board-based Exergame balance training, the game intensity will be low for this group (Size of goal will be kept small for 3 times a week, 30 minutes per day for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming moderate intensity group
Description: Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept medium).for 3 times a week, 30 minutes per day for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming high intensity group
Description: Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept high).for 3 times a week, 30 minutes per day for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group exergaming
Description: Exer games training with soccer heading and penguin slide games(Wii Fitt balance games) for 3 times a week, 30 minutes per day for 8 weeks.
Study: NCT06164054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Rehabilitation System
Description: Participants of the experimental group will undergo treatment with Virtual Reality, both IVR and HB. The intervention will consist of 12 sessions lasting about 1 hour each and carried out with a frequency of three days per week within four weeks. Before starting the rehabilitation, arm illusion with the Handbox is inducted to explore the ability of the patients to perceive the virtual arm as their own. During this task, patients sit on a chair with the injured arm inside the Handbox and are invited to perform slow movements with the hand, such as moving the fingers one at a time and moving the wrist up and down. Moreover, they are invited to keep their attention to the virtual arm project on the screen that follows their natural movements. The arm illusion lasts 3 minutes, and the embodiment questionnaire is administered. Then, the treatment starts with IVR and HB sessions, which are counterbalanced to avoid the learning effect

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional therapy
Description: Participants randomly assigned to the control group will receive rehabilitation treatment as per usual clinical practice. Specifically, patients will be directed to rehabilitation facilities according to standard clinical rehabilitation pathways. They will be assigned to a physiotherapist who will administer the rehabilitation treatment for the upper limb impairment. Patients in the control group will receive the same amount of rehabilitation for the recovery of upper limb impairment as the treatment group, which means 3 physiotherapy sessions lasting 1 hour 3 times a week for 4 weeks.
Study: NCT04932148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental HD
Description: Starting haemodialysis at twice weekly frequency

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional HD
Description: Starting haemodialysis at thrice weekly frequency
Study: NCT04947189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel-D (Seivteronel in combination with dexamethasone)
Description: Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Use of docetaxel chemotherapy for solid tumours
Study: NCT04602845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 50ug Fentanyl intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 50ug Fentanyl intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: 50mg Fentanyl intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: 50mg Fentanyl intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 2.5mg midazolam in 2ml normal saline intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: 3mg Remimazolam in 2ml normal saline intravenously
Study: NCT05904483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFA
Description: PFA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFA
Description: PFA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFA
Description: PFA
Study: NCT04648020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine HCl Mucoadhesive Buccal Tablet
Description: 100 μg of clonidine per tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mucoadhesive Buccal Tablet
Description: Placebo
Study: NCT05159050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-loaded tumor penetrating microparticles
Description: Paclitaxel-loaded TPM, suspended in 0.5 L of 0.1% (w/v) polysorbate 80 in 0.9% sodium chloride is instilled into the peritoneal cavity over 3 to 5 minutes. Mixing of TPM is achieved by putting patient in 5 different positions for about 80 minutes.~Dose escalation, the starting dose of TPM is 50 mg/m\^2 paclitaxel-equivalents. Dose escalation will follow the Accelerated Titration Design. The dose levels to which patients will be assigned in sequential cohorts are listed below.~Dose escalation schedule of TPM, Dose Level 1\*: 50 mg/m\^2; Dose Level 2: 100 mg/m\^2; Dose Level 3: 135 mg/m\^2; Dose Level 4: 175 mg/m\^2; Dose Level 5: 200 mg/m\^2~\*Starting Dose
Study: NCT06375148

Intervention type: OTHER
Intervention: Enteral nutrition
Description: prone position ventilation

Intervention type: OTHER
Intervention: Enteral nutrition
Description: prone position ventilation

Intervention type: OTHER
Intervention: Enteral nutrition
Description: prone position ventilation

Intervention type: OTHER
Intervention: Enteral nutrition
Description: prone position ventilation
Study: NCT05212207

Intervention type: OTHER
Intervention: CGM, smartwatch, and electronic diary
Description: Participants wear a CGM and a smartwatch while keeping an electronic diary with information such as meals, sleep, and activity.
Study: NCT01596426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso
Description: granisetron transdermal system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV granisetron
Description: IV granisetron
Study: NCT05076851

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxalutamide
Description: Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
Study: NCT06465667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard
Description: The Dashboard intervention, representing current standard of care, will consist of a standard e-mail message with a link to the dashboard and text explanation. No performance data will be included in the e-mail, and links will not be monitored for clickthrough with repeat e-mail.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard
Description: The Dashboard intervention, representing current standard of care, will consist of a standard e-mail message with a link to the dashboard and text explanation. No performance data will be included in the e-mail, and links will not be monitored for clickthrough with repeat e-mail.
Study: NCT05143385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: * Those patients who are randomly assigned as the intervention group will be given an explanatory session on the use of the video game console, controllers and game accessories.~* The intervention will begin 15 calendar days after admission.~* The intervention will be carried out once a week with a duration of 20 minutes with one of the games chosen by the patient together with the physiotherapist.~* The end of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions completed in order to participate in the study.~* The intervention will be carried out with an average of six sessions in each patient, including in the study those who perform a minimum of four sessions. However, the interventions will continue until hospital discharge.~* After completion of the clinical trial, a registry table will be drawn up quantifying the number of sessions for each patient and the type of session:
Study: NCT06324812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)
Description: subcutaneous injection，611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks
Study: NCT05975788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staphylococcus and Neisseria Tablets
Description: Staphylococcus and Neisseria tablets is used as an adjuvant treatment drug for respiratory disease in acute attack period, such as chronic tracheitis, bronchitis and various types of colds. It has been proved to effectively shorten the course of disease. In this study, Staphylococcus and Neisseria tablets will be administered with 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months according to clinicians.
Study: NCT04908982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81mg
Description: 81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
Study: NCT05097430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-focused brief intervention
Description: The primary intervention component is the Check Your Drinking (CYD) intervention - an electronically-delivered brief intervention designed to assess and provide personalized feedback regarding the quantity, frequency, and severity of one's alcohol consumption. Additionally, intervention condition participants who are identified as having a concurrent substance use concern or who may be experiencing depression will receive information about local resources that can assist with such concerns.
Study: NCT04696003

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter
Description: The amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intraamniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. and the amnioinfusion (about 100 ml/h, 2400 ml/day) with artificial amniotic fluid (Amnion Flush Solution, CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h under periodic ultrasound using the standard i.v. pump.
Study: NCT05547984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Mobility Cup
Description: Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Acetabular component
Description: Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
Study: NCT05543317

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT
Description: Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.